Revance Therapeutics (RVNC) Misses Q2 EPS by 2c

Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.88), $0.02 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• TSMC targets 2029 for panel-level CoPoS packaging in AI chip push - DigiTimes
• Summit Hotel Properties refinances $650M credit facility through 2031